JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2022, 71(5):224-233 | DOI: 10.5817/CSF2022-5-224

Promising anticonvulsant N-[(2,4-dichlorophenyl) methyl]-2-(2,4-dioxo-1H-quinazolin-3-yl) acetamide: dose-dependent study and evaluation of anticonvulsant action spectrum in vivo and in silico

Sergiy Shtrygol'1,*, Sergiy Zalevskyi1, Mariia Mishchenko1, Diana Shtrygol'2, Hanna Severina3, Wassim El Kayal3, Victoriya Georgiyants3
1 Department of Pharmacology and Pharmacotherapy, National University of Pharmacy, Kharkiv, Ukraine
2 Department of Neurology, Psychiatry, Narcology and Medical Psychology, School of Medicine, V. N. Karazin Kharkiv National University, Ukraine
3 Department of Pharmaceutical Chemistry, National University of Pharmacy, Kharkiv, Ukraine

The anticonvulsant spectrum of the original promising anticonvulsant N-[(2,4-dichlorophenyl) methyl]-2-(2,4-dioxo-1H-quinazolin-3-yl) acetamide was studied. The compound had a pronounced anticonvulsant effect, significantly reducing the mortality of mice in models of seizures induced by pentylenetetrazole, picrotoxin, strychnine, and caffeine. In the thiosemicarbazideinduced seizure model, the test compound did not reduce mortality. The obtained results indicated that the mechanism of anticonvulsant action involved GABA-ergic (effective in models of pentylenetetrazole and picrotoxin-induced seizures), glycinergic (efficiency in the strychnine model of paroxysms), and adenosinergic (effectiveness in the model of caffeine induced seizures). Molecular docking of a promising anticonvulsant to anticonvulsant biotargets follow the mechanisms of chemo-induced seizures, namely GABA, glycine, and adenosine receptors type A2A, GABAAT, and BCAT enzymes. The conformity between in vivo and in silico studies results was revealed.

Keywords: quinazoline; acetamide; dose; anticonvulsant effect; GABA receptor; A2A receptor; Gly receptor; docking

Received: June 16, 2022; Accepted: September 16, 2022; Published: May 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Shtrygol' S, Zalevskyi S, Mishchenko M, Shtrygol' D, Severina H, El Kayal W, Georgiyants V. Promising anticonvulsant N-[(2,4-dichlorophenyl) methyl]-2-(2,4-dioxo-1H-quinazolin-3-yl) acetamide: dose-dependent study and evaluation of anticonvulsant action spectrum in vivo and in silico. Čes. slov. farm. 2022;71(5):224-233. doi: 10.5817/CSF2022-5-224.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Chen Z., Brodie, M. J., Liew D., Kwan, P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic Drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018; 75: 279-286. Go to original source... Go to PubMed...
    2. Bigelow M. D., Kouzani A. Z. Neural stimulation systems for the control of refractory epilepsy: a review. J. Neuroeng. Rehabil. 2019; 16(1): 126. Go to original source... Go to PubMed...
    3. El Kayal W. M., Mokhamad W., Shtrygol S. Yu., Zalevskyi S. V., Abu Shark A., Tsyvunin V. V., Kovalenko S. M., Bunyatyan N. D., Perekhoda L. O., Severina H. I., Georgiyants V. A. Synthesis, in vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2,4-dioxo- 1,4-dihydroquinazolin-3(2H)-yl)acetamide. Eur. J. Med. Chem. 2019; 180(15): 134-142. Go to original source... Go to PubMed...
    4. Bunyatyan N. D., Severina H. I., El Kayal W. M., Zalevskyi S. V., Shtrygol S. Yu., Abu Shark A., Tsyvunin V. V., Kompantsev D. V., Shevchenko A. M., Kovalenko S. N., Georgiyants V. A., Ogay M. A., Khadzhieva Z. J. Synthesis and anticonvulsant activity of new 2-(4-oxo-2-thioxo-1,4-dihydro-3(2H)quinazolinyl)acetamides. Pharm. Chem. J. 2020; 54(1): 1-8. Go to original source...
    5. Zalevskyi S. V., Shtrygol' S. Yu., Shtrygol' D. V. Psychotropic properties and acute toxicity of 2-(2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)-N-[(2,4-dichlorophenylmethyl]- acetamide - a promising anticonvulsant. Pharm. & Drug Toxic. 2021; 15(6): 363-371.
    6. Golovenko M. Ya., Gromov L. O. Preclinical study of the specific activity of potential anticonvulsants: Guidelines. K.: DC of the Ministry of Health of Ukraine 2003.
    7. Hock F. J. Drug Discovery and Evaluation: Pharmacological Assays. Switzerland: Springer International Publishing 2016. Go to original source...
    8. Mishchenko M. V., Shtrygol' S. Yu. The range of anticonvulsant action and acute toxicity of 5-[(Z)-(4-nitrobenzylidene)]- 2-(thiazol-2-ylimino)-4-thiazolidinone. Pharm. & Drug Toxic. 2020; 14(6): 389-396.
    9. Kavraiskyi, D. P., Shtrygol' S. Yu., Georgiyants V. А., Severina H. І. Experimental determination of the spectrum of anticonvulsant action of new pyrazole [3,4-d] pyrimidine-4-one derivatives. SсienceRise: Pharm. Sci. 2016; 1: 10-17.
    10. Tsyvunin V., Shtrygol' S., Shtrygol' D. Digoxin enhances the effect of antiepileptic drugs with different mechanism of action in the pentylenetetrazole-induced seizures in mice. Epilepsy Res. 2020; 167: 106465. Go to original source... Go to PubMed...
    11. Trott O., Olson A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010; 31: 455-461. Go to original source... Go to PubMed...
    12. Protein Data Bank. URL: http://www.rcsb.org/pdb/home/ home.do (Date of access: 04.02.2021).
    13. Masiulis S., Desai R., Uchański T., et al. GABAAreceptor signaling mechanisms revealed by structural pharmacology. Nature 2019; 565: 454-459. Go to original source... Go to PubMed...
    14. Golovenko M. Ya., Larionov V. B., Reder A. S., Valivodz' I. P. An effector analysis of the interaction of propoxazepam with antagonists of GABA and glycine receptors. Neurochem. J. l 2017; 11(4): 302-308. Go to original source...
    15. van Koert R. R., Bauer P. R., Schuitema I., Sander J. W., Visser G. H. Caffeine and seizures: A systematic review and quantitative analysis. Epilepsy Behav. 2018; 80: 37-47. Go to original source... Go to PubMed...
    16. Golovenko M. Ya., Reder A. S., Larionov V. B., Valivodz' I. P. The effect of propoxazepam on development of thiosemicarbazide-induced GABA-deficient seizures in mice. Clin. Pharm. 2017; 21(2): 34-40. Go to original source...
    17. Miller P. S., Aricescu A. R. Crystalstructureof a human GABAA receptor. Nature 2014; 512(7514): 270-275. Go to original source... Go to PubMed...
    18. Storici P., Capitani G., de Biase D., Moser M., John R. A., Jansonius J. N., Schirmer T. Crystal structure of GABA aminotransferase, a target for antiepileptic drug therapy. Biochem. 1999; 38(27): 8628-8634. Go to original source... Go to PubMed...
    19. Huang X., Shaffer P. L., Ayube S., Bregman H., Chen H., Lehto S. G., Gingras J. Crystal structures of human glycine receptor α3 bound to a novel class of analgesic potentiators. Nat. Struct. Mol. Biol. 2017; 24(2): 108-113. Go to original source... Go to PubMed...
    20. Sun B., Bachhawat P., Chu M. L.-H., Wood M., Ceska T., Sands Z. A., Kobilka B. K. Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket. Proc. Natl. Acad. Sci. 2017; 114: 2066-2071. Go to original source... Go to PubMed...
    21. Goto M., Miyahara I., Hirotsu K. Structural Determinants for Branched-chain Aminotransferase Isozyme-specific Inhibition by theAnticonvulsant Drug Gabapentin. J. Biolog. Chem. 2005; 280: 37246-37256. Go to original source... Go to PubMed...
    22. Severina H. I., Skupa O. O., Voloshchuk N. I., Saidov N., Bunyatyan V. A., Kovalenko S. M., Georgiyants V. A. Molecular docking, ADMET study and in vivo pharmacological research of N-(3,4-dimetoxyphenyl)-2-{[2-methyl-6-(pyridine-2-yl)-pyrimidin-4-yl]thio} acetamide as a promising anticonvulsant. Res. Results in Pharm. 2020; 6(2): 27-41. Go to original source...
    23. Santos R., Ursu O., Gaulton A. A comprehensive map of molecular drug targets. Nat. Rev. Drug. Discov 2017; 16(1): 19-34. Go to original source... Go to PubMed...
    24. Shtrygol' S. Yu., Zalevskyi S. V., Gorbach T. V. Promising anticonvulsant 2-(2,4-dioxo-1,4-dihydroquinazolin- 3(2H)-yl)-N-[(2,4-dichlorophenyl)methyl]-acetamide: the influence on the content of neuroactive amino acids and 8-isoprostane in the mouse brain under the model of thiosemicarbazide-induced seizures. Pharm. & Drug Toxic. 2022; 16(1): 19-26.

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.